Pharmaceutical Executive: August 2023

A Fierce Focus On Unmet Need

August 11, 2023

Executive Profile

44

8

From public defender to spearheading the adoption of innovative drugs, Wendy Short Bartie, senior VP and general manager for the hematology and cell therapy division at Bristol Myers Squibb, has remained a steadfast patient advocate—working to fulfill unmet medical needs and bring treatments to as many people as possible.

Pharma's ESG Equation: Materiality and Strategy are Key

August 11, 2023

Feature

44

8

Life sciences executives who are confronted by too many choices in launching their environmental, social, and governance programs can leverage these two foundational tools to hone in on the set of issues, actions, and disclosures they should prioritize to create value.

AI and Drug 'Re-Innovation'

August 10, 2023

Columns

44

8

The application of artificial intelligence is steadily finding a home in the pharma industry, but these tools may have unprecedented potential in a more nascent niche along the life sciences continuum: drug development.

Democratizing Insight

August 06, 2023

From the Editor

44

8

Here at Pharmaceutical Executive®, we are already planning our editorial calendar for 2024. And each year we go through this process, I consider this a time of reflection to see where the industry has come, what topics always seem to be on the tips of everyone’s tongues, and what should be a topic of focus. Along with artificial intelligence (AI) being top of mind, other topics that come into my inbox again and again relate to diversity, equity, and inclusion (DE&I) and addressing unmet medical needs.